Single-cell CBD Biomarkers of Inflammation Reduction in People Living With HIV

University of Florida

Status and phase

Completed

Phase 4

Conditions

Chronic Inflammation

Treatments

Drug: CBD oil

Study type

Interventional

Funder types

Other

Identifiers

NCT05209867

IRB202101624 -A

OCR41346 (Other Identifier)

Details and patient eligibility

About

People living with HIV (PLWH) are affected by comorbidities appearing to be strongly related to chronic inflammation, a condition characterizing PLWH.

The investigators propose to study the effects of CBD on inflammation in PLWH, and establish the molecular role of different immune cells in this process. The investigators plan to use single cell RNA-sequencing (scRNAseq) to isolate CBD-specific cellular phenotypes from five persons with HIV who will provide blood samples before and after taking CBD.

Enrollment

4 patients

Sex

All

Ages

21 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Willingness to take CBD and to participate in follow up for two months
Older than 21 and younger than 60
Under antiretroviral therapy for 5+ years and suppressed viral load (CD4 count <350cells/ml)

Exclusion criteria

Conditions/medications that may impair the immune response, e.g., rheumatoid arthritis, cancer, diabetes, chronic infections, CAD (Cold agglutinin disease), cellulitis, autoimmune diseases such as lupus, sarcoidosis
All medications that may affect inflammation such as aspirin, steroids, statins; CD4 count <350cells/ml), pregnancy, and current marijuana or CBD use (urine drug screen)
UF(University of Florida)/Shands staff and students will not be considered for enrollment